•The Phase 3 SCOUT-HCM trial demonstrated the efficacy and safety of Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
•Data was presented at the American College of Cardiology (ACC) conference, reinforcing the drug's safety and efficacy profile in a younger demographic.